Development of CDK4/6 Inhibitors: A Five Years Update

The inhibition of cyclin dependent kinases 4 and 6 plays a role in aromatase inhibitor resistant metastatic breast cancer. Three dual CDK4/6 inhibitors have been approved for the breast cancer treatment that, in combination with the endocrine therapy, dramatically improved the survival outcomes both...

Descripción completa

Detalles Bibliográficos
Autores principales: Ammazzalorso, Alessandra, Agamennone, Mariangela, De Filippis, Barbara, Fantacuzzi, Marialuigia
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7967197/
https://www.ncbi.nlm.nih.gov/pubmed/33803309
http://dx.doi.org/10.3390/molecules26051488

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7967197/
https://www.ncbi.nlm.nih.gov/pubmed/33803309
http://dx.doi.org/10.3390/molecules26051488

Ejemplares similares